Skip to main content
Premium Trial:

Request an Annual Quote

Meridian Bioscience Receives CE Mark for Illumigene Malaria Test

NEW YORK (GenomeWeb) – Meridian Bioscience today announced it has received the CE Mark for its Illumigene Malaria test, developed with the US Centers for Disease Control and Prevention and Senegal's Cheikh Anta Diop University.

Using loop-mediated isothermal amplification technology, Illumigene Malariaresults are available in under an hour and are 80,000 times more sensitive at detecting the malaria parasite than conventional tests, the firm said in a statement.

"Faster and more accurate diagnosis is vital in the fight against malaria," Cheikh Anta Diop University professor Daouda Ndiaye said in a statement. "Earlier diagnosis enables the correct treatment to be prescribed which leads to better clinical outcomes for the person with malaria and keeps malaria treatments for the right people."

The firm said Meridian Bioscience Europe will distribute Illumigene Malaria in Europe, the Middle East, and Africa, while its global distribution network will extend the test's reach to additional international markets.

The test is the tenth assay for the Illumigene platform, which also offers tests for Clostridium difficile, Group B StrepGroup A StrepMycoplasma pneumoniaeBordetella pertussis, HSV 1 and 2, chlamydia, and gonorrhea.